Ultragenyx Pharmaceutical UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, we're going to get started. Thank you, everyone, for joining us for our inaugural UBS Global Biopharma Conference. My name is Jun Li, one of the biotech analysts at UBS. For this session, we have Emil Kakkis, CEO of Ultragenyx, and CFO of Ultragenyx as well. Thank you. Emil, thanks for spending time with us. For the audience who may be new to the story, could you spend a few minutes describing the focus of the company and the recent updates, and why investors should pay attention to Ultragenyx now?
Thanks, Jun. Thanks for having us, and Howard and the whole Ultragenyx team's happy to be here. Ultragenyx is a company that's been on the public markets since 2014. We're a rare and ultrarare company with six approved products in those 12 years on the market, heading toward $1 billion in revenue next year, and we expect to be profitable next year, meaningful profitability achieved. We've been working in a wide variety of types of drugs, gene therapies, biologics like antibodies or enzymes, and small molecules as well. We're agnostic as to mode and focusing on the best possible treatment strategy. We had two misses this year that have been of challenge for the stock, including osteogenesis imperfecta, setrusumab program, as well as in the Angelman program. Between the two, the OI setrusumab program, we think, has great data that we're going to continue to pursue.
We can talk more about that at some point. The Angelman program, we have to set aside at this point. Because of that, we've implemented important cost-cutting, approximately 20% of our staff, and reduced R&D spend by 50%. I'm sure Howard can talk more about what we did, but the point where the meaningful cost reductions have put us on path to be profitable, full-year profitability next year, and put us in charge of our future. In addition, we sold two PRVs, which added about $350 million to the balance sheet, giving us more than $700 million cash. We are a balance sheet that's full, and we should be adding commercial cash over the coming year. So we're in a very good situation from the standpoint of profitability, but we did have two big catalyst misses put us where we are today.
We think we're going to turn that corner and move forward with the continued growth of our base business, plus the two gene therapy launches, which are doing well, and the continued pipeline focus on a narrower, tighter footprint of high-value programs, which includes setrusumab for OI, as well as our OTC program and an early-stage program. We're encouraged by where we're at, but we certainly have had two hits that have put us in a more difficult place. I'm confident in our future and our ability to be profitable and generate meaningful R&D value as well as commercial value going forward.
As Emil said, you've undertaken some really difficult but major reductions in the goal towards profitability. What are some pushes and pulls into your profitability assumptions? Once you achieve that profitability in 2027, how sustainable is that going forward?
Howard, do you want to answer that one? Since it's right up your alley.
Yes. We project profitability in 2027, and we've said we intend to sustain it. The assumptions that get us there, we have a base business of four programs that's been growing north of 20% since we've gone commercial. Then we have the two gene therapy launches that we're in the process of now, and I think we'll probably come back to some more detail on those. That gives you a growth rate on the top line where we can control our spend on R&D and SG&A. We gave some guidance on that on our last call. We will keep R&D next year under $350 million, and we'll keep SG&A under $375 million. Those facts get us to profitability. Importantly, as Emil mentioned, we now have the balance sheet strength to not need to raise to get to profitability.
That's a pretty big corner to turn as a biotech to be able to say all of that in one year's time.
What proportion of the remaining headcount is focused on R&D versus SG&A?
You want to put that out?
Yeah, I do not know that we have guided directly to that. I think most of our costs, as in most companies, are people-based, a large percentage of them. We think, look, ultimately what we think is that the R&D that we have guided to can support the commercial programs, because there is still some R&D that goes on there, plus a very focused base of spend on R&D and the UX143 program and UX016 and the DTX301 programs. That is really the core of it. Our SG&A is meant to support the six programs we have on market globally.
Does the R&D spend take into account the potential new trial of setrusumab in osteogenesis imperfecta, which we will get into in a little bit?
Yeah, it absolutely does. It does.
All right. Yeah, we do not have to change our guidance at all for that.
How much of the new launches need to be contributing to 2027 revenue to maintain your profitable guidance and sustainability of that profitability?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
